Exercise combined with blood flow restriction in people with chronic kidney disease
Tests exercise with blood flow restriction in healthy adults and people with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Exploring the Effects of Exercise Combined With BFRT on Healthy and Patients With CKD
Key facts
- Where
- Tainan, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 85 years old?
Source: NCT07288905, who can take part
Where in Taiwan
- National Cheng Kung University HospitalTainan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cheng Kung University
- Trial code
- NCT07288905
- Record updated
- 17 December 2025
- Original description
Investigate the effects of exercise training on the cardiopulmonary function and exercise capacity in healthy and CKD patientsRead full original descriptionShow less
The Feasibility and Effects of Exercise Training Combined With Blood Flow Restriction Training on Exercise Capacity and Exercise Tolerance in Patients With Chronic Kidney Disease
Investigate the effects of exercise training on the cardiopulmonary function and exercise capacity in healthy and CKD patients
Inclusion: Aged 20~85 years old; Aged 20~85 years old; eGFR< 90 ml/min/1.73 m2 over 3 months; Stable condition without worsening in the past 3 months; Ability to understand and follow verbal commends and cooperate with an exercise training program.
Exclusion: Severe uncontrolled metabolic diseases (e.g., hyperthyroidism, diabetes, hypertension, hyperlipidemia, etc.); Severe pulmonary or cardiovascular diseases (e.g., pulmonary hypertension, chronic obstructive pulmonary disease (COPD), heart failure, cardiac arrhythmia); Presence of a cardiac pacemaker or a history of myocardial infarction within the past six months; Severe musculoskeletal or neuromuscular disorders (e.g., advanced arthritis, limb amputation, post-polio syndrome, Parkinson's disease); Unstable vital signs (e.g., systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥90 mmHg, requiring vasopressors, or resting heart rate >100 bpm); Kidney function impairment; Cancer; Severe uncontrolled metabolic diseases (e.g., hyperthyroidism, diabetes, hypertension, hyperlipidemia, etc.); Severe pulmonary or cardiovascular diseases (e.g., pulmonary hypertension, chronic obstructive pulmonary disease (COPD), heart failure, cardiac arrhythmia); Presence of a cardiac pacemaker or a history of myocardial infarction within the past six months; Severe musculoskeletal or neuromuscular disorders (e.g., advanced arthritis, limb amputation, post-polio syndrome, Parkinson's disease); Unstable vital signs (e.g., systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥90 mmHg, requiring vasopressors, or resting heart rate >100 bpm); Diagnosed systemic diseases under ongoing treatment (e.g., systemic lupus erythematosus, cancer, malignancies); Abnormal blood biochemical parameters (e.g., white blood cell count <2500/mm³, hemoglobin <8 mg/dL, total bilirubin >3 mg/dL, liver enzymes (GOT/AST, GPT/ALT) >3 times the upper limit of normal, platelet count <75,000/mm³; Prone to bruising; Recent inflection < 1 month; Pregnancy; Simultaneously participating in other research; CKD; Sensory or motor dysfunctions that affect walking ability.
Healthy.